Lupinacci, R. Et Al. 2023. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine , vol.41, no.5 , 1142-1152.

Lupinacci, R., Rupp, R., Wittawatmongkol, O., Jones, J., Quinones, J., Ulukol, B., ... Dagan, R.(2023). A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine , vol.41, no.5, 1142-1152.

Lupinacci, Robert Et Al. "A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)," Vaccine , vol.41, no.5, 1142-1152, 2023

Lupinacci, Robert Et Al. "A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)." Vaccine , vol.41, no.5, pp.1142-1152, 2023

Lupinacci, R. Et Al. (2023) . "A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)." Vaccine , vol.41, no.5, pp.1142-1152.

@article{article, author={Robert Lupinacci Et Al. }, title={A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)}, journal={Vaccine}, year=2023, pages={1142-1152} }